Malmberg KJ - Search Results

1

Natural killer cell-mediated immunosurveillance of human cancer.

Malmberg KJ, Carlsten M, Björklund A, Sohlberg E, Bryceson YT, Ljunggren HG. Malmberg KJ, et al. Semin Immunol. 2017 Jun;31:20-29. doi: 10.1016/j.smim.2017.08.002. Epub 2017 Sep 6. Semin Immunol. 2017. PMID: 28888619 Review.

2

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Söderström K, Levitskaya J, Kiessling R. Malmberg KJ, et al. J Clin Invest. 2002 Nov;110(10):1515-23. doi: 10.1172/JCI15564. J Clin Invest. 2002. PMID: 12438449 Free PMC article.

3

Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?

Malmberg KJ. Malmberg KJ. Cancer Immunol Immunother. 2004 Oct;53(10):879-92. doi: 10.1007/s00262-004-0577-x. Epub 2004 Jul 28. Cancer Immunol Immunother. 2004. PMID: 15338206 Free PMC article. Review.

4

Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation.

Schaffer M, Malmberg KJ, Ringdén O, Ljunggren HG, Remberger M. Schaffer M, et al. Among authors: malmberg kj. Transplantation. 2004 Oct 15;78(7):1081-5. doi: 10.1097/01.tp.0000137103.19717.86. Transplantation. 2004. PMID: 15480179

5

KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation.

Malmberg KJ, Schaffer M, Ringdén O, Remberger M, Ljunggren HG. Malmberg KJ, et al. Mol Immunol. 2005 Feb;42(4):531-4. doi: 10.1016/j.molimm.2004.07.037. Mol Immunol. 2005. PMID: 15607809 Review.

6

Escape from immune- and nonimmune-mediated tumor surveillance.

Malmberg KJ, Ljunggren HG. Malmberg KJ, et al. Semin Cancer Biol. 2006 Feb;16(1):16-31. doi: 10.1016/j.semcancer.2005.07.007. Epub 2005 Sep 2. Semin Cancer Biol. 2006. PMID: 16140546 Review.

7

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R. Norell H, et al. Among authors: malmberg kj. Cancer Res. 2006 Jun 15;66(12):6387-94. doi: 10.1158/0008-5472.CAN-06-0029. Cancer Res. 2006. PMID: 16778217

8

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients.

Hanson MG, Ozenci V, Carlsten MC, Glimelius BL, Frödin JE, Masucci G, Malmberg KJ, Kiessling RV. Hanson MG, et al. Among authors: malmberg kj. Cancer Immunol Immunother. 2007 Jul;56(7):973-84. doi: 10.1007/s00262-006-0261-4. Epub 2006 Dec 2. Cancer Immunol Immunother. 2007. PMID: 17143612 Free PMC article. Clinical Trial.

9

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

Carlsten M, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren HG, Malmberg KJ. Carlsten M, et al. Among authors: malmberg kj. Cancer Res. 2007 Feb 1;67(3):1317-25. doi: 10.1158/0008-5472.CAN-06-2264. Cancer Res. 2007. PMID: 17283169

10

Prospects for the use of NK cells in immunotherapy of human cancer.

Ljunggren HG, Malmberg KJ. Ljunggren HG, et al. Among authors: malmberg kj. Nat Rev Immunol. 2007 May;7(5):329-39. doi: 10.1038/nri2073. Nat Rev Immunol. 2007. PMID: 17438573 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters